Lama Tawfek Hasan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lama Tawfek Hasan has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Israa Ahmed Qutob
Faculty of Medicine, Alexandria University, Alexandria, Egypt
2 shared publications - Mohanad Yaser Assem
Faculty of medicine, Mansoura University, Daqahlia, Egypt
2 shared publications - Farah Shalaan
Medical Oncology and Malignant Hematology Department, National Cancer Institute, Cairo University, Cairo, Egypt
1 shared publication - Hadeel Khaled Albaoni
Faculty of Pharmacy, Jordan University of Science and Technology, Amman, Jordan
1 shared publication - Hana A. Smeda
Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Zawia, Zawia, Libya
1 shared publication - Hind Abdulhay
Faculty of medicine, Mansoura University, Daqahlia, Egypt
1 shared publication
Latest Publications
- Open Access
- 1 October 2026
- Published by Springer Nature in Discover Oncology
Invasive ductal breast carcinoma with orbital or/and ocular metastasis: rare case series and systematic review
- 1 October 2026
- Published by Springer Nature in Discover Oncology
Open AccessInvasive ductal breast carcinoma with orbital or/and ocular metastasis: rare case series and systematic review
- Open Access
- 10 August 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (9) , 6024-6032
Monocarboxylate transporter 1 deficiency: a rare case report and systematic review of genetically confirmed cases
Monocarboxylate transporter 1 (MCT1) deficiency is an ultra-rare autosomal recessive metabolic disorder caused by pathogenic variants in the SLC16A1 gene, which encodes a proton-linked transporter of lactate, pyruvate, and ketone bodies. Few cases have been genetically confirmed worldwide, and diagnosis is often delayed due to nonspecific clinical features and the absence of characteristic metabolic markers. We report the case of a 5-year-old Egyptian boy with recurrent episodes of ketoacidosis and neurological symptoms, who was confirmed by whole-exome sequencing to have homozygous SLC16A1 pathogenic variants. Clinical data, biochemical findings, treatment course, and follow-up were documented in accordance with CARE guidelines. To contextualize this case, we conducted a systematic review of the literature following PRISMA 2020 guidelines, identifying genetically confirmed cases of MCT1 deficiency and summarizing clinical, genetic, and therapeutic insights. The patient presented with high anion gap metabolic acidosis (pH 6.8, bicarbonate 5.2 mmol/L) and normal glucose, lactate, and ammonia levels, consistent with impaired monocarboxylate transport. He developed severe rebound hypokalemia (serum potassium 1.7 mmol/L) during bicarbonate therapy, necessitating intensive correction. He recovered with supportive management, including careful fluid and electrolyte replacement. Our systematic review identified seven eligible studies, encompassing eight patients across six countries. Age of onset ranged from 2 months to 6 years, with clinical presentations including recurrent vomiting, lethargy, seizures, and metabolic crises. While outcomes varied, early recognition and supportive management were associated with more favorable neurodevelopmental trajectories. This study highlights the diagnostic and therapeutic challenges of MCT1 deficiency. The case illustrates not only the typical metabolic phenotype but also treatment-related complications such as hypokalemia. Findings from the systematic review emphasize the importance of genetic testing for early recognition, multidisciplinary management, and the need for greater clinical awareness of this emerging metabolic disorder. Expanding patient registries and investigating genotype–phenotype correlations are essential to improve outcomes in affected individuals.
- 10 August 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (9) , 6024-6032
Open AccessMonocarboxylate transporter 1 deficiency: a rare case report and systematic review of genetically confirmed cases
Monocarboxylate transporter 1 (MCT1) deficiency is an ultra-rare autosomal recessive metabolic disorder caused by pathogenic variants in the SLC16A1 gene, which encodes a proton-linked transporter of lactate, pyruvate, and ketone bodies. Few cases have been genetically confirmed worldwide, and diagnosis is often delayed due to nonspecific clinical features and the absence of characteristic metabolic markers. We report the case of a 5-year-old Egyptian boy with recurrent episodes of ketoacidosis and neurological symptoms, who was confirmed by whole-exome sequencing to have homozygous SLC16A1 pathogenic variants. Clinical data, biochemical findings, treatment course, and follow-up were documented in accordance with CARE guidelines. To contextualize this case, we conducted a systematic review of the literature following PRISMA 2020 guidelines, identifying genetically confirmed cases of MCT1 deficiency and summarizing clinical, genetic, and therapeutic insights. The patient presented with high anion gap metabolic acidosis (pH 6.8, bicarbonate 5.2 mmol/L) and normal glucose, lactate, and ammonia levels, consistent with impaired monocarboxylate transport. He developed severe rebound hypokalemia (serum potassium 1.7 mmol/L) during bicarbonate therapy, necessitating intensive correction. He recovered with supportive management, including careful fluid and electrolyte replacement. Our systematic review identified seven eligible studies, encompassing eight patients across six countries. Age of onset ranged from 2 months to 6 years, with clinical presentations including recurrent vomiting, lethargy, seizures, and metabolic crises. While outcomes varied, early recognition and supportive management were associated with more favorable neurodevelopmental trajectories. This study highlights the diagnostic and therapeutic challenges of MCT1 deficiency. The case illustrates not only the typical metabolic phenotype but also treatment-related complications such as hypokalemia. Findings from the systematic review emphasize the importance of genetic testing for early recognition, multidisciplinary management, and the need for greater clinical awareness of this emerging metabolic disorder. Expanding patient registries and investigating genotype–phenotype correlations are essential to improve outcomes in affected individuals.